Skip to content

San Antonio Breast Cancer Symposium 2022

At the 45th annual San Antonio Breast Cancer Symposium (SABCS), leading faculty from the Mass General Cancer Center will join over 10,000 clinicians and scientists from around the world to contribute their latest advancements in breast cancer research.

The San Antonio Breast Cancer Symposium (SABCS) is an annual event that brings together thousands of clinicians and scientists from around the world in an effort to share the latest advancements in breast cancer research. It is designed to provide updates on clinical, translational, and basic research findings through a forum dedicated to interaction and education among international researchers and healthcare professionals.

SABCS 2022 marks the 45th anniversary of the event, with over 10,000 clinicians and scientists set to attend and present their recent findings. The event comprises of formal lectures, poster presentations, forums, and case discussions. Members of the Mass General Cancer Center will present at SABCS, sharing their research in the prevention, diagnosis, and treatment of breast cancer and premalignant breast disease.

Tuesday, December 6, 2022

Clinical Research Workshop
8:00 am: Stars at Night Ballroom 1&2
Moderator: Aditya Bardia

Spotlight Poster Discussion: Impact of Race on Clinical, Socioeconomic, and Genomic Characteristics, Clinical Trial Participation, and Receipt of Genotype-matched Therapy Among Patients With Metastatic Breast Cancer
5:00 pm: Hemisfair Ballroom 1&2
Rupali Sood, Lianne Ryan, Andrzej Niemierko, Laura Spring, Dejan Juric, Steven Isakoff, Seth Wander, Jennifer Shin, Naomi Ko, Leif Ellisen, Beverly Moy, Aditya Bardia, Neelima Vidula

Clinical Scholar Award: Virtual Molecular and Precision Medicine (vMAP) Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic-community Collaboration
5:00 pm: Hall 1
Lindsey Mortensen, Jennifer Keenan, Elizabeth Abraham, Sarah Padden, Annie Ma, Elyssa Denault, Lianne Ryan, Arielle J. Medford, Leif W. Ellisen, Joel H. Schwartz, Aditya Bardia, Laura M. Spring

Side Effects of the mRNA COVID-19 Vaccines in Women Treated for Breast Cancer
5:00 pm: Hall 1
Brooke Juhel, Cheryl L. Brunelle, Madison Bernstein, Louisa H. Smith, Amanda W. Jung, Elizabeth K. Hausman, Loryn K. Bucci, George E. Naoum, Alphonse G. Taghian

The Impact of Adjuvant Chemotherapy, Including Taxanes, on Breast Cancer-Related Lymphedema Risk
5:00 pm: Hall 1
Amanda W. Jung, Brooke Juhel, Louisa H. Smith, Cheryl L. Brunelle, Elizabeth K. Hausman, Loryn K. Bucci, George E. Naoum, Alphonse G. Taghian

Investigating NF1 Mutations in Circulating Tumor DNA of Patients With Hormone-receptor Positive (HR+) Breast Tumors Resistant to CDK4/6 Inhibition (CDK4/6i): A Retrospective Clinical Analysis
5:00 pm: Hall 1
Maxwell Lloyd, Lianne Ryan, Arielle Medford, Laura Spring, Jennifer Keenan, Neelima Vidula, Beverly Moy, Dejan Juric, Leif Ellisen, Aditya Bardia, Seth Wander

Datopotamab Deruxtecan (Dato-DXd), a TROP2 Antibody-drug Conjugate, vs. Investigators’ Choice of Chemotherapy in Previously-treated, Inoperable or Metastatic HR+/HER2– Breast Cancer: TROPION-Breast01
5:00 pm
Bardia A, Kalinsky K, Tsurutani J, Hamilton EP, Sohn JH, Park KH, Park YH, Im S-A, Lee KS, Dastur D, Haddad V, Khan S, Xu B, Pistilli B, Rugo HS

Phase II Study of Talazoparib, a PARP Inhibitor, in Somatic BRCA1/2 Mutant Metastatic Breast Cancer Identified by Cell-free DNA or Tumor Tissue Genotyping
5:00 pm
Neelima Vidula, Senthil Damodaran, Erica Blouch, Nora Horick, Nathan Royce Ruffle-Deignan, Manali Bhave, Ami N. Shah, Leticia Varella, Vandana Abramson, Joseph Sparano, Leif W. Ellisen, Ishraq Alim, Harry Ostrer, Hope S. Rugo, Aditya Bardia

Wednesday, December 7, 2022

Oral Presentation Session: TRIO-US B-12 TALENT: Neoadjuvant Trastuzumab Deruxtecan With or Without Anastrozole for HER2-low, HR+ Early Stage Breast Cancer
9:30 am: Hall 3
Hurvitz SA, Bardia A (Presenter), Press MF, Wang LS, McAndrew NP, Chan D, Phan V, Villa D, Tetef ML, Chamberlain E, Abdulla N, lomis T, Spring LM, Applebaum S, Dakhil S, DiCarlo B, Kim DD, Kirimis E, Lawler WE, Master AK, McCann K, Hayashi E, Kivork C, Chauv J

Impact of HER2 Low Status on Clinical Outcomes in Participants With 1-3 Positive Lymph Nodes, HR+/HER2- Breast Cancer With Recurrence Score
9:45 am: Hall 3
Spring LM, Barlow WE, Bardia A, SHarma P, Pusztai L, Hortobagyi GN, Kalinsky K

Educational Session: Antibody Drug Conjugates: Future Directions and Opportunities—Mechanisms of Resistance
3:00 pm: Stars at Night Ballroom 1&2
Leif Ellisen

Spotlight Poster Discussion: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases
5:00 pm: Stars at Night Ballroom 3&4
Rachel Freedman, Rebecca Gelman, Beverly Moy, Cesar Santa-Maria, Adam Brufsky, Catherine Van Poznak, Ciara O’Sullivan, Michelle Melisko, Julie Nangie, Nadia Ashai, Wendy Chen, Nabihah Tayob, Siyang Ren, Karen Smith, Christine Cotter, Robyn Burns, Jennifer Savoie, Antonio Wolff, Ian Krop, Eric Winer, Mothaffar Rimawi, Nancy Lin, Yasmeen Rauf

The Impact of Co-existing Ductal Carcinoma in situ in Invasive Early Hormone Receptor Positive Breast Cancer on the Genomic and Clinical Risk of Recurrence
5:00 pm: Hall 1
Yael Bar, Kfir Bar, Didi Feldman, Judith Ben-Dror, Meishar Shahoha, Ahuva Weiss-Meilik, Nachum Dershowitz, Ido Wolf, Amir Sonnenblick

Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events (AEs) From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs. Treatment of Physician’s Choice (TPC) in HR+/HER2- Metastatic Breast Cancer
5:00 pm: Hall 1
Tolaney SM, Schmid P, Bardia A, Marmé F, Loirat D, Sharma P, Wang H, Fu O, Verret W, Rugo HS

ELEVATE: A Phase 1b/2, Open-label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer
5:00 pm
Rugo HS, Bardia A, Cortés J, Curigliano G, Hamilton E, Hurvitz SA, Loibl S, Scartoni S, Sahmoud T, Grzegorzewski K, Habboubi N, O'Shaughnessy J

lidERA Breast Cancer: A Phase III Adjuvant Study of Giredestrant (GDC-9545) vs. Physician’s Choice of Endocrine Therapy in Patients With Estrogen Receptor+, HER2– Early Breast Cancer
5:00 pm
Schmid P, Geyer Jr CE, Harbeck N, Rimawi MF, Survitz SA, Martín M, Loi S, Saji S, Jung KH, Werutsky G, Stroyakovsky DL, López-Valverde V, Davis M, Badovinac Crnjevic T, Perez-Moreno PD, Bardia A

Thursday, December 8, 2022

Spotlight Poster Discussion: Impact of ESR1 Mutations on Selective Estrogen Receptor Degraders and Modulators: An Integrated Liquid-biopsy and Pharmacodynamics Approach
7:00 am: Stars at Night Ballroom 3&4
Gerratana L, Roncato R, Sturlese M, Davis AA, Velimirovic M, Reduzzi C, Clifton KK, Hensing WL, Shah AN, Dai CS, D'Amico P, Medford AJ, Franzoni A, Cucciniello L, Wehbe F, Wander SA, Belletti B, Gradishar W, Behdad A, Damante G, Ma CX, Puglisi F, Bardia A, Cristofanilli M

Changes in the Genomic Spectrum of Actionable Alterations in HER2 Negative Metastatic Breast Cancer in Serial Cell Free DNA (cfDNA) Analysis
7:00 am: Hall 1
Yael Bar, Jennifer C. Keenan, Lianne Ryan, Dejan Juric, Jennifer Shin, Seth A. Wander, Laura Spring, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff, Aditya Bardia, Neelima Vidula

Oral Presentation Session: Overall Survival Results From EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), vs. Investigator's Choice of Endocrine Monotherapy for ER+/HER2- Advanced Breast Cancer
8:30 am: Hall 3
Bardia A, Bidard F-C, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc f, Dillon P, Babu S, Waters S, Deleu I, García-Sáenz JA, Bria E, Cazzaniga ME, Aftimos P, Cortés J, Tonini G, Sahmoud T, Habboubi N, Grzegorzewski K, Kaklamani V

Spotlight Poster Discussion: Exploratory Gene Expression Analysis of coopERA Breast Cancer (BC): A Study Evaluating Neoadjuvant Giredestrant vs. Anastrozole Alone and in Combination With Palbociclib in ER-positive, HER2-negative Untreated Early BC
5:00 pm: Stars at Night Ballroom 1&2
Chibly AM, Fernando TM, Metcalfe C, Hafner M, Owusu-Manu G, Hurvitz SA, Bardia A, Fasching PA, Park YH, Quiroga V, Steinseifer J, Perez-Moreno P, Moore HM

Spotlight Poster Discussion: Exploratory Subgroup and Biomarker Analyses of acelERA Breast Cancer: Phase II study of Giredestrant (GDC-9545) vs. Physician’s Choice of Endocrine Therapy for Previously Treated, Estrogen Receptor+, HER2– Advanced Breast Cancer
5:00 pm: Stars at Night Ballroom 1&2
Lim E, Chavez-MacGregor M, Bardia A, Sohn JH, Moore HM, Shivhare M, Martinalbo J, Roncoroni L, Perez-Moreno PD, Martin M

Spotlight Poster Discussion: Combination Therapy With the AKT Inhibitor, Ipatasertib, Endocrine therapy, and a CDK4/6 Inhibitor for Hormone Receptor Positive (HR+)/HER2 Negative Metastatic Breast Cancer (MBC): Results From the Phase I TAKTIC Trial
5:00 pm: Stars at Night Ballroom 1&2
Seth A. Wander, Jennifer C. Keenan, Andrzej Niemierko, Laura M. Spring, Dejan Juric, Jeffrey G. Supko, Neelima Vidula, Steven J. Isakoff, Lianne Ryan, Sarah Padden, Elizabeth Fisher, Amber Newton, Beverly Moy, Leif W. Ellisen, Douglas S. Micalizzi, Aditya Bardia

Spotlight Poster Discussion: Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–positive/HER2–negative Breast Cancer
5:00 pm: Stars at Night Ballroom 1&2
Meric-Bernstam F, Krop I, Juric D, Kogawa T, Hamilton EP, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Bardia A

Cell-free DNA Detection of GATA3 Mutations in Metastatic Hormone Receptor Positive Breast Cancer: A Retrospective, Observational Multi-institutional Analysis
5:00 pm: Hall 1
A. Medford, M. Velimirovic, A. Niemierko, W. Hensing, A. Davis, K. Clifton, J. Keenan, C. Dai, L. Kiedrowski, A. Shah, L. Gerratana, L. Spring, L. Ellisen, R. Doebele, M. Cristofanilli, A. Bardia

TRK Inhibitor in a Patient With Metastatic Triple Negative Breast Cancer and NTRK Fusions Identified via Cell-free DNA Analysis
5:00 pm: Hall 1
Jennifer C. Keenan, Arielle J. Medford, Lauren Oshry, Baris Boyraz, Charles S. Dai, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Tasos Gogakos, Rachel H. Occhiogrosso, Phoebe Ryan, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia

Identification of Mechanisms of Acquired Resistance to Ribociclib Plus Endocrine Therapy Using Baseline and End-of-Treatment Circulating Tumor DNA Samples in the MONALEESA-2, -3, and -7 Trials
5:00 pm: Hall 1
Andre F, Solovieff N, Su F, Bardia A, Neven P, Yap Y-S, Tripathy D, Lu Y-S, Slamon D, Chia SK, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results From POLARIS
5:00 pm: Hall 1
Tripathy D, Blum JL, Deng S, McCune SL, Patel K, Wang Y, Lakhanpal S, Karuturi MS, Zhang Z, Deshpande C, Montelongo MZ, Gauthier E, Liu Y, Rocque GB, Bardia A

Co-occurring Alterations in PALB2 Germline Carriers Identified by Liquid Biopsy in Patients With Advanced Breast Cancer
5:00 pm: Hall 1
N. Chen, R. Nanda, F. M. Howard, N. Vidula, J. Yen, L.M. Drusbosky, L. Bucheit

Comparison of Cell-free DNA Genomics of Breast Cancer Associated-chest Wall Disease vs. Age & Subtype Matched Controls With Metastatic Breast Cancer Not Involving the Chest Wall
5:00 pm: Hall 1
Neelima Vidula, Lianne Ryan, Andrzej Niemierko, Dejan Juric, Steven J. Isakoff, Francys Verdial, Marjan Azin, Laura A. Petrillo, Beverly Moy, Leif W. Ellisen, Shadmehr Demehri, Aditya Bardia

Friday, December 9, 2022

Spotlight Poster Discussion: Cell-free DNA Monitoring in a Phase II Study of Adjuvant Endocrine Therapy With CDK 4/6 Inhibitor Ribociclib for Localized ER+/HER2- Breast Cancer (LEADER)
7:00 am
A. Medford, L. Scarpetti, A. Niemierko, S. Isakoff, B. Moy, S. Wander, E. Deluca, E. Abraham, J. Shin, L. Schnipper, A. Comander, T. Mulvey, L. Ellisen, A. Bardia, L. Spring

Spotlight Poster Discussion: Endocrine Therapy New Insights
7:00 am: Stars at Night Ballroom 1&2
Seth Wander

Spotlight Poster Discussion: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: Final 10-year Analysis
7:00 am: Stars at Night Ballroom 3&4
Sara Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Chau Dang, Denise Yardley, Beverly Moy, Kelly Marcom, Kathy Albain, Hope Rugo, Matthew Ellis, Iuliana Shapira, Antonio Wolff, Lisa Carey, Romualdo Barroso, Michelle DeMeo, Molly DiLullo, Ann Partridge, Adrienne Waks, Clifford Hudis, Harold Burstein, Aleix Prat, Eric Winer, Ian Krop

Impact of HER2 Low Status on Clinical Outcomes in Participants With 1-3 Positive Lymph Nodes, HR+/HER2- Breast Cancer With Recurrence Score < 25 Randomized to Endocrine Therapy +/- Chemotherapy: Results From SWOG S1007 (RxPONDER)
7:00 am: Hall 1
Laura Spring, William E. Barlow, Aditya Bardia, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky

Ipsilateral Infusions Are Not Associated With Increased Risk of Breast Cancer-related Lymphedema in Patients Enrolled in a Prospective Screening Program
7:00 am: Hall 1
Cheryl L. Brunelle, Amanda W. Jung, Louisa H. Smith, Kayla Daniell, Maria S. Asdourian, Loryn K. Bucci, Brooke Juhel, Elizabeth K. Hausman, George E. Naoum, Alphonse G. Taghian

Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
7:00 am: Hall 1
Bardia A, Krop I, Meric-Bernstam, Tolcher AW, Mukohara T, Lisberg A, Shimizu T, Hamilton Ep, Spira AI, Papadopoulos KP, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Kogawa T

Genetic Alterations in Breast Cancer Associated With MDM2 Dependency and Sensitivity to the MDM2 Inhibitor Milademetan
7:00 am: Hall 1
Bidard F-C, Bello Roufai D, Medford AJ, Tirunagaru V, Doebele RC, Bardia A

Oral Presentation Session: Second Interim Analysis of Overall Survival (OS) From the TROPiCS-02 Phase 3 Study of Sacituzumab Govitecan (SG) vs. Treatment of Physician’s Choice (TPC) in Patients With HR+/HER2- Advanced Breast Cancer
2:30 pm: Hall 3
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri K, Delaney R Fu O, Wang H, Verret W, Tolaney SM

Educational Session: State of the Art Radiotherapy: Reducing Toxicity and Increasing Options—The Role of Advanced Radiation Technology in Reducing Toxicity
3:00 pm: Stars at Night Ballroom 3&4
Rachel Jimenez